Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Medica Scientia Innovation Research (MedSIR ARO)
Woman and Man
Between 18 years
and 99 years
Medica Scientia Innovation Research (MedSIR ARO)
Update Il y a 4 ans
Étude MedOPP038: étude de phase 1, en escalade de dose, évaluant la tolérance de l'association du trastuzumab emtansine (T-DM1) et de la doxorubicine, chez des patients ayant un cancer du sein métastatique HER2-positif. [essai clos aux inclusions]
Etude MedOPP038 : Essai clinique de Phase I, multicentrique, évaluant l'association du trastuzumab emtansine (T-DM1) et de la doxorubicine dans le traitement du cancer du sein métastatique HER2-positi...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Medica Scientia Innovation Research (MedSIR ARO)
Update Il y a 4 ans
A phase IIa clinical trial to evaluate the safety and efficacy of osirmertinib in first-line patients withadvanced or metastatic non-small cell lung cancer (AZENT study) Ensayo clínico de seguridad y eficacia de osirmertinib como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico localmente avanzado o metástasico (estudio AZENT)
To evaluate the efficacy of osimertinib (AZD9291), in terms of the objective response rate in patients with advanced non-squamous NSCLC with EGFR mutations and the EGFR T790M mutation at diagnosis as ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Medica Scientia Innovation Research (MedSIR ARO)
Update Il y a 6 ans
Étude MedOPP038: étude de phase 1, en escalade de dose, évaluant la tolérance de l'association du trastuzumab emtansine (T-DM1) et de la doxorubicine, chez des patients ayant un cancer du sein métastatique HER2-positif.
Etude MedOPP038 : Essai clinique de Phase I, multicentrique, évaluant l'association du trastuzumab emtansine (T-DM1) et de la doxorubicine dans le traitement du cancer du sein métastatique HER2-positi...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman
Between 18 years
and 99 years
Medica Scientia Innovation Research (MedSIR ARO)
Update Il y a 4 ans
Étude PARSIFAL - MedOPP067 : étude de phase 2, randomisée, comparant l’efficacité et la tolérance d'un traitement par palbociclib associé au fulvestrant ou au letrozol chez des patientes ayant un cancer du sein métastatique, HER2-, ER+. [essai clos aux inclusions]
PARSIFAL - MedOPP067 - A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negat...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Medica Scientia Innovation Research (MedSIR ARO)
Update Il y a 4 ans
- Ensaio clínico prospectivo, de fase IIa, multicêntrico, sem ocultação e não controlado para avaliar a eficacia e tolerabilidade do tratamento com eribulina como agente único de primeira linha em doentes com cancro da mama metastizado HER2 negativo previamente tratados com taxanos
- Determinar a eficácia da eribulina como agente único no tratamento de primeira linha de doentes com cancro da mama metastizado HER2 negativo, que progrediram após o tratamento (neo)adjuvante c...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Medica Scientia Innovation Research (MedSIR ARO)
Update Il y a 4 ans
A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status Ensayo clínico de fase II de la actividad de radio 223 en pacientes con cáncer de próstata metastásico resistente a la castración (CPRCm) con progresión asintomática durante el tratamiento con acetato de abiraterona o enzalutamida y en función del estado mutacional del gen ARV7
To assess the efficacy of radium-223 in asymptomatic patients with mCRPC who have progressed while on abiraterone acetate or enzalutamide treatment. Evaluar la eficacia del radio 223 en paciente...
Country
None
organs
None
Specialty
None
unknown
More information
Woman
Between 18 years
and 99 years
Medica Scientia Innovation Research (MedSIR ARO)
Update Il y a 6 ans
Étude PARSIFAL - MedOPP067 : étude de phase 2, randomisée, comparant l’efficacité et la tolérance d'un traitement par palbociclib associé au fulvestrant ou au letrozol chez des patientes ayant un cancer du sein métastatique, HER2-, ER+.
PARSIFAL - MedOPP067 - A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negat...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Medica Scientia Innovation Research (MedSIR ARO)
Update Il y a 4 ans
Trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer Ensayo para evaluar la eficacia y seguridad de nal-IRI en pacientes con cáncer de mama HER2 negativo con metástasis cerebrales en progresión
To assess the efficacy of nal-IRI in patients with HER2- negative metastatic breast cancer who have documented CNS progression following WBRT, SRS and/or surgery, as determined by the RANO-BM criteria...
Country
None
organs
None
Specialty
None
unknown
More information